NHS England rolled out tirzepatide for weight management in cohorts after NICE TA1026 in December 2024: 3 Cohort 1 (from June 2025): adults with a body mass index (BMI) of 40 or higher and at least four of five weight-related conditions (type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease)
Footnotes Author Disclosure Statement The authors do not have any disclosures
Enrichment strategies also help to support precision medicine by targeting and tailoring interventions to those patients who would be expected to benefit from them based on results from subtyping (endotyping or phenotyping) using clinical or multiomics data, as discussed further later in this chapter
TGF- ligands bind and activate a heteromeric complex of type I and type II transmembrane serine/threonine kinase receptors
Note what time of day you injected tirzepatide and any side effects you felt over the following 48 hours
Effect of tesamorelin on visceral fat and liver fat in experimental models: a randomized investigation
